Form 8-K - Current report:
SEC Accession No. 0001213900-25-011325
Filing Date
2025-02-07
Accepted
2025-02-07 16:18:10
Documents
15
Period of Report
2025-02-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0230283-8k_hoth.htm   iXBRL 8-K 36301
2 OPINION OF SHEPPARD MULLIN RICHTER & HAMPTON LLP ea023028301ex5-1_hoth.htm EX-5.1 15114
3 GRAPHIC ex5-1_001.jpg GRAPHIC 8392
  Complete submission text file 0001213900-25-011325.txt   245594

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE hoth-20250207.xsd EX-101.SCH 3039
5 XBRL LABEL FILE hoth-20250207_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE hoth-20250207_pre.xml EX-101.PRE 22375
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0230283-8k_hoth_htm.xml XML 3923
Mailing Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036
Business Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036 (646)756-2997
Hoth Therapeutics, Inc. (Filer) CIK: 0001711786 (see all company filings)

EIN.: 821553794 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38803 | Film No.: 25601996
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)